secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2026-10-09T20:42:27+00:00
Accession:  0001193125-26-419174
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vaxcyte raises ~$1.10B via concurrent offerings: $575M 1.50% converts due 2032 and $64/share stock sale
--------------------------------------------------------------------------------

- $575M aggregate 1.50% convertible senior notes due Oct 15, 2032; initial conversion price ~$89.60/share (11.1607 shares per $1,000); $75M over-allotment exercised in full.
- Equity offering of 7,412,500 shares at $64.00 plus 400,000 pre-funded warrants at $63.999; underwriters' 30-day option for 1,171,875 more shares exercised in full.
- Net proceeds ~$544.3M from the equity sale and ~$558.7M from the notes after discounts and expenses; both offerings closed Oct 9, 2026.
- Interest on the notes payable semi-annually Apr 15 and Oct 15, starting Apr 15, 2027; provisional redemption permitted on/after Oct 22, 2029 if the stock tops 130% of conversion price.
- Jefferies LLC and Leerink Partners LLC led both deals; notes are senior unsecured obligations under an indenture with U.S. Bank Trust Company as trustee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312526419174/0001193125-26-419174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312526419174/d150490d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-419174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer